Skip to main content

Advertisement

Table 4 Univariate and multivariate analyses for overall survival

From: Feasibility and efficacy of gemcitabine and docetaxel combination chemotherapy for bone and soft tissue sarcomas: multi-institutional retrospective analysis of 134 patients

  Univariate analysis  
Factors HR (95% CI) p value
Age (years)
 <50 (vs. ≥50) 1.20 (0.76–1.89) 0.436
Tumor origin
 Bone (vs. soft tissue) 1.32 (0.77–2.27) 0.318
Primary site   0.633
 Trunk (vs. extremities) 0.85 (0.43–1.68) 0.639
 Retroperitoneum (vs. extremities) 0.65 (0.31–1.37) 0.259
 Visceral (vs. extremities) 1.15 (0.56–2.35) 0.702
Histological subtype   0.002
 UPS (vs. leiomyosarcoma) 1.24 (0.55–2.81) 0.608
 Others (vs. leiomyosarcoma) 2.54 (1.46–4.42) 0.001
Prior chemotherapy   0.126
 Second-line (vs. first-line) 1.38 (0.72–2.65) 0.332
 Third-or-greater line (vs. first-line) 1.90 (1.00–3.62) 0.052
Response to GD
 SD/PD (vs. CR/PR) 3.81 (1.37–10.55) 0.010
  Multivariate analysis  
Factors HR (95% CI) p value
Age (years)
 ≥50 (vs. <50)   
Tumor origin
 Bone (vs. soft tissue)   
Primary site
 Trunk (vs. extremities)   
 Retroperitoneum (vs. extremities)   
 Visceral (vs. extremities)   
Histological subtype
 UPS (vs. leiomyosarcoma)   
 Others (vs. leiomyosarcoma)   
Prior chemotherapy
 Second-line (vs. first-line)   
 Third-or-greater line (vs. first-line)   
Response to GD
 SD/PD (vs. CR/PR) 3.99 (1.42–11.22) 0.009